Revenue
2021
2022
2023
Vicapsys Life Sciences, Inc. (VICP)
Price$1.00Cached quote
Net income
2019
2020
2021
2022
2023
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
Financial statements
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — |
| Research & development | $15,267 | $13,097 | $17,698 | $102,180 | $98,983 |
| Operating expenses | $1.0M | $984,790 | $336,871 | $765,844 | $1.0M |
| Operating income | −$1.0M | −$984,790 | −$336,871 | −$765,844 | — |
| EBITDA | −$1.2M | −$953,501 | −$305,542 | — | — |
| Net income | −$1.2M | −$984,790 | −$236,871 | −$765,844 | −$1.4M |
| Basic EPSper basic share | -$0.03 | -$0.03 | -$0.01 | -$0.04 | -$0.13 |
| Diluted EPSper diluted share | -$0.03 | -$0.03 | -$0.01 | -$0.04 | -$0.13 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Potter Leonard / Wildcat Partner Holdings, LP / Wildcat Capital Management, LLC | 6.07M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data